<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34738307</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of thrombosis and haemostasis : JTH</Title><ISOAbbreviation>J Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Persistent endotheliopathy in the pathogenesis of long COVID syndrome - Reply to comment from von Meijenfeldt et al.</ArticleTitle><Pagination><StartPage>270</StartPage><EndPage>271</EndPage><MedlinePgn>270-271</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jth.15578</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fogarty</LastName><ForeName>Helen</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8161-7931</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Coagulation Centre, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karampini</LastName><ForeName>Ellie</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4082-076X</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>Andrew S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University Maternity Hospital Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Soracha E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Jamie M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-1162-8739</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>James S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-0309-3313</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Coagulation Centre, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Irish COVID-19 Vasculopathy Study (iCVS) investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Thromb Haemost</MedlineTA><NlmUniqueID>101170508</NlmUniqueID><ISSNLinking>1538-7836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Thromb Haemost. 2022 Jan;20(1):267-269. doi: 10.1111/jth.15580</RefSource><PMID Version="1">34731533</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>James S. O'Donnell has served on the speaker's bureau for Baxter, Bayer, Novo Nordisk, Sobi, Boehringer Ingelheim, Leo Pharma, Takeda, and Octapharma. He has also served on the advisory boards of Baxter, Sobi, Bayer, Octapharma CSL Behring, Daiichi Sankyo, Boehringer Ingelheim, Takeda, and Pfizer. He has also received research grant funding awards from 3M, Baxter, Bayer, Pfizer, Shire, Takeda, 3M, and Novo Nordisk. The remaining authors have no conflict of interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>5</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34738307</ArticleId><ArticleId IdType="pmc">PMC8646468</ArticleId><ArticleId IdType="doi">10.1111/jth.15578</ArticleId><ArticleId IdType="pii">S1538-7836(22)02748-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>von Meijenfeldt FA, Havervall S, Adelmeijer J, Thalin C, Lisman T. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Comment from von Meijenfeldt et al. J Thromb Haemost. 2021. doi:10.1111/jth.15280</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15280</ArticleId><ArticleId IdType="pmc">PMC8646477</ArticleId><ArticleId IdType="pubmed">34731533</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D&#x2010;dimer levels in convalescent COVID&#x2010;19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19(4):1064&#x2010;1070. doi:10.1111/jth.15267</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15267</ArticleId><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt FA, Havervall S, Adelmeijer J, et al. Sustained prothrombotic changes in COVID&#x2010;19 patients 4 months after hospital discharge. Blood Adv. 2021;5:756&#x2010;759. doi:10.1182/bloodadvances.2020003968</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003968</ArticleId><ArticleId IdType="pmc">PMC7857699</ArticleId><ArticleId IdType="pubmed">33560386</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021;19:2546&#x2010;2553. doi:10.1111/jth.15490</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulshof AM, Braeken DCW, Ghossein&#x2010;Doha C, et al. Hemostasis and fibrinolysis in COVID&#x2010;19 survivors 6 months after intensive care unit discharge. Res Pract Thromb Haemost. 2021;5:e12579. doi:10.1002/rth2.12579</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12579</ArticleId><ArticleId IdType="pmc">PMC8463660</ArticleId><ArticleId IdType="pubmed">34595368</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13&#x2010;von Willebrand factor axis in COVID&#x2010;19 patients. J Thromb Haemost. 2020;19(2):513&#x2010;521. doi:10.1111/jth.15191</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15191</ArticleId><ArticleId IdType="pmc">PMC7753796</ArticleId><ArticleId IdType="pubmed">33230904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SE, Fogarty H, Karampini E, et al. ADAMTS13 regulation of VWF multimer distribution in severe COVID&#x2010;19. J Thromb Haemost. 2021;19(8):1914&#x2010;1921. doi:10.1111/jth.15409</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15409</ArticleId><ArticleId IdType="pmc">PMC8237059</ArticleId><ArticleId IdType="pubmed">34053187</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SE, Curley GF, Lavin M, et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID&#x2010;19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2021;192(4):714&#x2010;719. doi:10.1111/bjh.17273</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17273</ArticleId><ArticleId IdType="pubmed">33326604</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post&#x2010;acute sequelae of COVID&#x2010;19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169. doi:10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, et al. &#x2018;Long&#x2010;COVID&#x2019;: a cross&#x2010;sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID&#x2010;19. Thorax. 2021;76:396&#x2010;398. doi:10.1136/thoraxjnl-2020-215818</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>